Merck & Co., Inc. Financial Highlights Package Second Quarter 2021 Table of Contents Table 1: GAAP P&L....................................................................................1 Table 1a: GAAP P&L – Current Year and Prior Year by Quarter.................2 Table 2a: GAAP to Non-GAAP Reconciliation 2Q21 and June YTD 21.......3 Table 2b: GAAP to Non-GAAP Reconciliation 2Q20 and June YTD 20.......4 Table 3: Sales - Current Year and Prior Year by Quarter...........................5 Table 3a: Sales – U.S. / Ex- U.S. 2Q21........................................................6 Table 3b: Sales – U.S. / Ex- U.S. June YTD 21............................................7 Table 3c: Sales – Pharmaceutical Geographic Split....................................8 Table 4: Other (Income) Expense .............................................................9 -- 1 of 10 -- Sales 11,402 $ 9,353 $ 22% 22,029 $ 19,641 $ 12% Costs, Expenses and Other Cost of sales 3,104 2,747 13% 6,303 5,576 13% Selling, general and administrative 2,281 2,085 9% 4,468 4,276 4% Research and development 4,321 2,085 * 6,732 4,260 58% Restructuring costs (1) 82 82 0% 380 152 * Other (income) expense, net (103) (387) -73% (558) (325) 72% Income from Continuing Operations Before Taxes 1,717 2,741 -37% 4,704 5,702 -18% Income Tax Provision 503 396 741 891 Net Income from Continuing Operations 1,214 2,345 -48% 3,963 4,811 -18% Less: Net Income (Loss) Attributable to Noncontrolling Interests 1 4 5 (1) Net Income from Continuing Operations Attributable to Merck & Co., Inc. 1,213 $ 2,341 $ -48% 3,958 $ 4,812 $ -18% Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests 332 $ 661 $ -50% 766 $ 1,409 $ -46% Net Income Attributable to Merck & Co., Inc. 1,545 $ 3,002 $ -49% 4,724 $ 6,221 $ -24% Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders: Income from Continuing Operations 0.48 $ 0.93 $ -48% 1.56 $ 1.90 $ -18% Income from Discontinued Operations 0.13 $ 0.26 $ -50% 0.30 $ 0.56 $ -46% Net Income 0.61 $ 1.19 $ -49% 1.87 $ 2.46 $ -24% Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders: Income from Continuing Operations 0.48 $ 0.92 $ -48% 1.56 $ 1.89 $ -17% Income from Discontinued Operations 0.13 $ 0.26 $ -50% 0.30 $ 0.55 $ -45% Net Income 0.61 $ 1.18 $ -48% 1.86 $ 2.45 $ -24% Average Shares Outstanding 2,533 2,527 2,532 2,531 Average Shares Outstanding Assuming Dilution 2,540 2,536 2,540 2,542 Tax Rate from Continuing Operations (2) 29.3% 14.4% 15.8% 15.6% * 100% or greater (2) The effective income tax rates for the second quarter and first six months of 2021 reflect the unfavorable impact of a charge for the acquisition of Pandion Therapeutics, Inc. for which no tax benefit was recognized. Additionally, the effective income tax rate for the first six months of 2021 reflects a net tax benefit of $207 million related to the settlement of certain federal income tax matters. MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1 GAAP % Change GAAP % Change 2Q21 On June 2, 2021, Merck completed the spinoff of products from its women’s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon & Co. (Organon) through a distribution of Organon’s publicly traded stock to company shareholders. The historical results of the women’s health, biosimilars and established brands businesses that were contributed to Organon in the spin-off are excluded from sales and expenses below and reflected as discontinued operations in the company’s Consolidated Statements of Income provided below. 2Q20 June YTD 2021 June YTD 2020 (1) Represents separation and other related costs associated with restructuring activities under the company's formal restructuring programs. 1 -- 2 of 10 -- Sales 10,627 $ 11,402 $ 22,029 $ 10,288 $ 9,353 $ 19,641 $ 10,929 $ 10,948 $ 41,518 $ 22% 12% Costs, Expenses and Other Cost of sales 3,199 3,104 6,303 2,829 2,747 5,576 3,013 5,029 13,618 13% 13% Selling, general and administrative 2,187 2,281 4,468 2,191 2,085 4,276 2,060 2,619 8,955 9% 4% Research and development 2,412 4,321 6,732 2,175 2,085 4,260 3,349 5,788 13,397 * 58% Restructuring costs 297 82 380 70 82 152 113 310 575 0% * Other (income) expense, net (455) (103) (558) 62 (387) (325) (312) (253) (890) -73% 72% Income (Loss) from Continuing Operations Before Taxes 2,987 1,717 4,704 2,961 2,741 5,702 2,706 (2,545) 5,863 -37% -18% Income Tax Provision 238 503 741 495 396 891 380 69 1,340 Net Income (Loss) from Continuing Operations 2,749 1,214 3,963 2,466 2,345 4,811 2,326 (2,614) 4,523 -48% -18% Less: Net Income (Loss) Attributable to Noncontrolling Interests 4 1 5 (5) 4 (1) 2 3 4 Net Income (Loss) from Continuing Operations Attributable to Merck & Co., Inc. 2,745 1,213 3,958 2,471 2,341 4,812 2,324 (2,617) 4,519 -48% -18% Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests 434 332 766 748 661 1,409 617 523 2,548 -50% -46% Net Income (Loss) Attributable to Merck & Co., Inc. 3,179 $ 1,545 $ 4,724 $ 3,219 $ 3,002 $ 6,221 $ 2,941 $ (2,094) $ 7,067 $ -49% -24% Basic Earnings (Loss) per Common Share Attributable to Merck & Co., Inc. Common Shareholders: Income (Loss) from Continuing Operations 1.08 $ 0.48 $ 1.56 $ 0.98 $ 0.93 $ 1.90 $ 0.92 $ (1.03) $ 1.79 $ -48% -18% Income from Discontinued Operations 0.17 0.13 0.30 0.30 0.26 0.56 0.24 0.21 1.01 -50% -46% Net Income (Loss) 1.26 $ 0.61 $ 1.87 $ 1.27 $ 1.19 $ 2.46 $ 1.16 $ (0.83) $ 2.79 $ -49% -24% Earnings (Loss) per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders: Income (Loss) from Continuing Operations 1.08 $ 0.48 $ 1.56 $ 0.97 $ 0.92 $ 1.89 $ 0.92 $ (1.03) $ 1.78 $ -48% -17% Income from Discontinued Operations 0.17 0.13 0.30 0.29 0.26 0.55 0.24 0.21 1.00 -50% -45% Net Income (Loss) 1.25 $ 0.61 $ 1.86 $ 1.26 $ 1.18 $ 2.45 $ 1.16 $ (0.83) $ 2.78 $ -48% -24% Average Shares Outstanding 2,531 2,533 2,532 2,533 2,527 2,531 2,529 2,530 2,530 Average Shares Outstanding Assuming Dilution (1) 2,541 2,540 2,540 2,547 2,536 2,542 2,538 2,530 2,541 Tax Rate from Continuing Operations 8.0% 29.3% 15.8% 16.7% 14.4% 15.6% 14.0% -2.7% 22.9% * 100% or greater Sum of quarterly amounts may not equal year-to-date amounts due to rounding. Table 1a MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) (1) Because the company recorded a net loss in the fourth quarter of 2020, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive. Income from discontinued operations was also computed using average common shares outstanding. 2021 2Q June YTD 1Q 1Q 2Q 3Q 4Q Full Year 2020 % Change 2Q June YTD June YTD 2 -- 3 of 10 -- Second Quarter Cost of sales 3,104 $ 345 38 37 (3) 420 2,684 $ Selling, general and administrative 2,281 25 2 27 2,254 Research and development 4,321 16 6 1,765 (4) 1,787 2,534 Restructuring costs 82 82 82 - Other (income) expense, net (103) 117 (258) (141) 38 Income From Continuing Operations Before Taxes 1,717 (503) (128) 258 (1,802) (2,175) 3,892 Income Tax Provision (Benefit) 503 (98) (5) (15) (5) 57 (5) (11) (5) (67) 570 Net Income from Continuing Operations 1,214 (405) (113) 201 (1,791) (2,108) 3,322 Net Income from Continuing Operations Attributable to Merck & Co., Inc. 1,213 (405) (113) 201 (1,791) (2,108) 3,321 Earnings per Common Share Assuming Dilution from Continuing Operations 0.48 $ (0.16) (0.04) 0.08 (0.71) (0.83) 1.31 $ Tax Rate 29.3% 14.6% June YTD Cost of sales 6,303 $ 842 65 225 (3) 1,132 5,171 $ Selling, general and administrative 4,468 35 4 39 4,429 Research and development 6,732 34 13 1,765 (4) 1,812 4,920 Restructuring costs 380 380 380 - Other (income) expense, net (558) 89 (819) (730) 172 Income From Continuing Operations Before Taxes 4,704 (1,000) (462) 819 (1,990) (2,633) 7,337 Income Tax Provision (Benefit) 741 (187) (5) (56) (5) 180 (5) (260) (5) (323) 1,064 Net Income from Continuing Operations 3,963 (813) (406) 639 (1,730) (2,310) 6,273 Net Income from Continuing Operations Attributable to Merck & Co., Inc. 3,958 (813) (406) 639 (1,730) (2,310) 6,268 Earnings per Common Share Assuming Dilution from Continuing Operations 1.56 $ (0.32) (0.16) 0.25 (0.68) (0.91) 2.47 $ Tax Rate 15.8% 14.5% Only the line items that are affected by non-GAAP adjustments are shown. Adjustment Subtotal Non-GAAP MERCK & CO., INC. SECOND QUARTER AND SIX MONTHS ENDED JUNE 30, 2021 GAAP TO NON-GAAP RECONCILIATION - CONTINUING OPERATIONS (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) The table below reflects a reconciliation of GAAP to non-GAAP financial information on a continuing operations basis. As Organon results are reflected within discontinued operations, they are excluded from the financial information provided below. GAAP Acquisition and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Certain Other Items Table 2a Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect acquisition and divestiture-related costs. Amounts included in research and development expenses primarily reflect expenses for the amortization of intangible assets. Amounts included in other (income) expense, net, for the second quarter and six months period primarily reflect an increase in the estimated fair value measurement of liabilities for contingent consideration related to the termination of the Sanofi-Pasteur MSD joint venture and a loss on a forward exchange contract entered into in conjunction with the Organon spinoff. Amount included in other (income) expense, net, for the six month period is partially offset by royalty income related to the termination of the Sanofi-Pasteur MSD joint venture. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (3) Represents charges for the discontinuation of COVID-19 development programs. (5) Represent the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Certain other items for the six month period also includes a $207 million net tax benefit related to the settlement of certain federal income tax matters. (4) Includes a $1.7 billion charge for the acquisition of Pandion Therapeutics, Inc. 3 -- 4 of 10 -- Second Quarter Cost of sales 2,747 $ 580 25 605 2,142 $ Selling, general and administrative 2,085 44 11 55 2,030 Research and development 2,085 (63) 31 (32) 2,117 Restructuring costs 82 82 82 - Other (income) expense, net (387) 63 (511) (16) (464) 77 Income From Continuing Operations Before Taxes 2,741 (624) (149) 511 16 (246) 2,987 Income Tax Provision (Benefit) 396 (91) (3) (27) (3) 112 (3) 5 (3) (1) 397 Net Income from Continuing Operations 2,345 (533) (122) 399 11 (245) 2,590 Net Income from Continuing Operations Attributable to Merck & Co., Inc. 2,341 (533) (122) 399 11 (245) 2,586 Earnings per Common Share Assuming Dilution from Continuing Operations 0.92 $ (0.21) (0.05) 0.16 - (0.10) 1.02 $ Tax Rate 14.4% 13.3% June YTD Cost of sales 5,576 $ 968 93 1,061 4,516 $ Selling, general and administrative 4,276 157 22 179 4,097 Research and development 4,260 (23) 48 25 4,235 Restructuring costs 152 152 152 - Other (income) expense, net (325) 52 (598) (16) (562) 237 Income From Continuing Operations Before Taxes 5,702 (1,153) (315) 598 16 (854) 6,556 Income Tax Provision (Benefit) 891 (241) (3) (34) (3) 132 (3) 5 (3) (139) 1,030 Net Income from Continuing Operations 4,811 (912) (281) 466 11 (715) 5,526 Net Income from Continuing Operations Attributable to Merck & Co., Inc. 4,812 (912) (281) 466 11 (715) 5,527 Earnings per Common Share Assuming Dilution from Continuing Operations 1.89 $ (0.36) (0.11) 0.18 0.01 (0.28) 2.17 $ Tax Rate 15.6% 15.7% Only the line items that are affected by non-GAAP adjustments are shown. Non-GAAP Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative (SG&A) expenses reflect acquisition and divestiture-related costs, including $95 million of transaction costs in the six month period related to the acquisition of Arqule, Inc. Amounts included in research and development expenses primarily reflect a reduction in expenses related to a decrease in the estimated fair value measurement of liabilities for contingent consideration. Amounts included in other (income) expense, net, primarily reflect costs related to increases in the estimated fair value measurement of liabilities for contingent consideration, partially offset by royalty income related to the termination of the Sanofi-Pasteur MSD joint venture. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (3) Represent the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. GAAP Acquisition and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Certain Other Items Adjustment Subtotal The table below reflects a reconciliation of GAAP to non-GAAP financial information on a continuing operations basis. As Organon results are reflected within discontinued operations, they are excluded from the financial information provided below. MERCK & CO., INC. SECOND QUARTER AND SIX MONTHS ENDED JUNE 30, 2020 GAAP TO NON-GAAP RECONCILIATION - CONTINUING OPERATIONS (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 2b 4 -- 5 of 10 -- 1Q 2Q June YTD 1Q 2Q June YTD 3Q 4Q Full Year Nom % Ex-Exch % Nom % Ex-Exch % TOTAL SALES (1) $10,627 $11,402 $22,029 $10,288 $9,353 $19,641 $10,929 $10,948 $41,518 22 19 12 10 PHARMACEUTICAL 9,238 9,980 19,218 8,905 8,178 17,083 9,714 9,813 36,610 22 18 12 9 Oncology Keytruda 3,899 4,176 8,076 3,284 3,388 6,672 3,715 3,993 14,380 23 20 21 18 Alliance Revenue – Lynparza (2) 228 248 475 145 178 323 196 206 725 39 34 47 42 Alliance Revenue – Lenvima (2) 130 181 310 128 151 279 142 158 580 19 15 11 8 Vaccines (3) Gardasil / Gardasil 9 917 1,234 2,151 1,097 656 1,753 1,187 998 3,938 88 78 23 17 ProQuad / M-M-R II / Varivax 449 516 965 435 378 813 576 488 1,878 36 35 19 17 Pneumovax 23 171 152 323 256 117 373 375 339 1,087 30 27 -13 -16 RotaTeq 158 208 366 222 168 391 210 196 797 23 19 -6 -8 Vaqta 34 56 90 60 28 88 51 31 170 101 96 2 - Hospital Acute Care Bridion 340 387 727 299 224 524 320 355 1,198 72 67 39 35 Prevymis 82 93 174 60 63 123 77 80 281 47 41 42 36 Noxafil 67 66 133 94 73 168 79 82 329 -10 -14 -21 -24 Primaxin 65 60 125 51 64 115 74 62 251 -6 -14 8 - Cancidas 57 54 111 55 43 98 50 65 213 24 17 13 8 Invanz 57 48 104 64 43 108 51 53 211 10 3 -3 -5 Zerbaxa (8) (1) (9) 37 32 69 43 19 130 -104 -104 -113 -113 Immunology Simponi 214 202 416 215 191 406 209 223 838 5 -3 2 -6 Remicade 85 75 160 88 73 160 82 88 330 3 -3 - -6 Neuroscience Belsomra 79 78 157 79 84 163 81 83 327 -7 -6 -4 -5 Virology Isentress / Isentress HD 209 192 401 245 196 441 205 211 857 -2 -5 -9 -11 Cardiovascular Alliance Revenue - Adempas/Verquvo (4) 74 74 149 53 79 133 83 65 281 -7 13 12 23 Adempas (5) 55 74 129 56 57 113 55 53 220 29 23 15 7 Diabetes (6) Januvia 809 784 1,593 774 854 1,628 821 857 3,306 -8 -11 -2 -5 Janumet 486 477 962 503 490 993 506 472 1,971 -3 -8 -3 -7 Other Pharmaceutical (7) 581 546 1,130 605 548 1,149 526 636 2,312 - -5 -2 -6 ANIMAL HEALTH 1,418 1,472 2,890 1,214 1,101 2,314 1,220 1,168 4,703 34 27 25 21 Livestock 819 821 1,640 739 648 1,386 758 794 2,939 27 20 18 15 Companion Animals 599 651 1,250 475 453 928 462 374 1,764 44 38 35 31 Other Revenues (8) (29) (50) (79) 169 74 244 (5) (33) 205 -167 -1 -132 -15 2021 2020 2Q June YTD MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3 (6) Total Diabetes sales were $1,363 million and $1,330 million in the first and second quarter of 2021, respectively, and $1,353 million, $1,418 million, $1,405 million and $1,412 million in the first, second, third and fourth quarters of 2020, respectively. (7) Includes Pharmaceutical products not individually shown above. (8) Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Total Vaccines sales were $1,809 million and $2,293 million in the first and second quarter of 2021, respectively, and $2,155 million, $1,418 million, $2,521 million and $2,163 million in the first, second, third and fourth quarters of 2020, respectively. (4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (5) Net product sales in Merck's marketing territories. 5 -- 6 of 10 -- 2Q 2021 2Q 2020 % Change 2Q 2021 2Q 2020 % Change 2Q 2021 2Q 2020 % Change TOTAL SALES (1) $11,402 $9,353 22 $5,100 $4,322 18 $6,301 $5,031 25 PHARMACEUTICAL 9,980 8,178 22 4,647 3,958 17 5,333 4,220 26 Oncology Keytruda 4,176 3,388 23 2,347 2,043 15 1,829 1,345 36 Alliance Revenue - Lynparza (2) 248 178 39 124 105 18 124 73 70 Alliance Revenue - Lenvima (2) 181 151 19 88 98 -11 93 53 74 Vaccines (3) Gardasil / Gardasil 9 1,234 656 88 454 168 170 781 488 60 ProQuad / M-M-R II / Varivax 516 378 36 386 263 47 130 115 13 Pneumovax 23 152 117 30 100 21 * 52 96 -46 RotaTeq 208 168 23 111 100 11 97 68 43 Vaqta 56 28 101 22 17 34 34 11 199 Hospital Acute Care Bridion 387 224 72 197 107 84 190 117 62 Prevymis 93 63 47 37 28 29 56 35 61 Noxafil 66 73 -10 14 6 135 52 67 -23 Primaxin 60 64 -6 0 1 -90 60 63 -5 Cancidas 54 43 24 1 (2) -132 53 45 18 Invanz 48 43 10 (4) * 52 43 20 Zerbaxa (1) 32 -104 (2) 17 -111 1 15 -96 Immunology Simponi 202 191 5 202 191 5 Remicade 75 73 3 75 73 3 Neuroscience Belsomra 78 84 -7 14 22 -36 63 61 4 Virology Isentress / Isentress HD 192 196 -2 74 76 -3 118 120 -2 Cardiovascular Alliance Revenue - Adempas/Verquvo (4) 74 79 -7 81 73 10 (7) 6 * Adempas (5) 74 57 29 74 57 29 Diabetes (6) Januvia 784 854 -8 284 413 -31 500 441 13 Janumet 477 490 -3 74 143 -48 403 348 16 Other Pharmaceutical (7) 546 548 245 259 -5 301 289 4 ANIMAL HEALTH 1,472 1,101 34 459 342 34 1,012 759 33 Livestock 821 648 27 161 122 32 659 526 25 Companion Animals 651 453 44 298 220 36 353 233 51 Other Revenues (8) (50) 74 -167 (6) 22 -127 (44) 52 -184 * 200% or greater Sum of U.S. plus international may not equal global due to rounding. (3) Total Vaccines sales were $2,293 million in the second quarter of 2021 and $1,418 million in the second quarter of 2020. MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS SECOND QUARTER 2021 (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3a Global U.S. International (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (5) Net product sales in Merck's marketing territories. (6) Total Diabetes sales were $1,330 million in the second quarter of 2021 and $1,418 million in the second quarter of 2020. (7) Includes Pharmaceutical products not individually shown above. (8) Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. 6 -- 7 of 10 -- June YTD 2021 June YTD 2020 % Change June YTD 2021 June YTD 2020 % Change June YTD 2021 June YTD 2020 % Change TOTAL SALES (1) $22,029 $19,641 12 $9,890 $9,053 9 $12,139 $10,588 15 PHARMACEUTICAL 19,218 17,083 12 8,941 8,266 8 10,277 8,818 17 Oncology Keytruda 8,076 6,672 21 4,528 3,949 15 3,548 2,722 30 Alliance Revenue - Lynparza (2) 475 323 47 242 190 28 233 133 75 Alliance Revenue - Lenvima (2) 310 279 11 173 188 -8 137 91 50 Vaccines (3) Gardasil / Gardasil 9 2,151 1,753 23 766 629 22 1,385 1,124 23 ProQuad / M-M-R II / Varivax 965 813 19 718 596 20 246 217 13 Pneumovax 23 323 373 -13 173 203 -15 150 170 -12 RotaTeq 366 391 -6 229 241 -5 137 150 -8 Vaqta 90 88 2 47 47 1 43 41 4 Hospital Acute Care Bridion 727 524 39 364 250 46 363 274 32 Prevymis 174 123 42 72 55 31 103 68 51 Noxafil 133 168 -21 29 14 113 104 154 -32 Primaxin 125 115 8 1 -92 125 114 9 Cancidas 111 98 13 3 1 * 108 98 11 Invanz 104 108 -3 6 -94 104 102 2 Zerbaxa (9) 69 -113 (4) 37 -110 (5) 32 -116 Immunology Simponi 416 406 2 416 406 2 Remicade 160 160 160 160 Neuroscience Belsomra 157 163 -4 32 49 -34 125 114 10 Virology Isentress / Isentress HD 401 441 -9 145 151 -4 256 290 -12 Cardiovascular Alliance Revenue - Adempas/Verquvo (4) 149 133 12 149 122 22 11 -99 Adempas (5) 129 113 15 129 113 15 Diabetes (6) Januvia 1,593 1,628 -2 632 768 -18 961 860 12 Janumet 962 993 -3 158 256 -38 805 737 9 Other Pharmaceutical (7) 1,130 1,149 -2 485 513 -5 644 637 1 ANIMAL HEALTH 2,890 2,314 25 896 726 23 1,994 1,588 26 Livestock 1,640 1,386 18 318 284 12 1,322 1,102 20 Companion Animals 1,250 928 35 578 442 31 672 486 38 Other Revenues (8) (79) 244 -132 53 61 -13 (132) 182 -172 * 200% or greater Sum of U.S. plus international may not equal global due to rounding. (3) Total Vaccines sales were $4,102 million and $3,574 million on a global basis for June YTD 2021 and 2020, respectively. MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS JUNE YEAR-TO-DATE 2021 (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3b Global U.S. International (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (5) Net product sales in Merck's marketing territories. (6) Total Diabetes sales were $2,693 million and $2,772 million on a global basis for June YTD 2021 and 2020, respectively. (7) Includes Pharmaceutical products not individually shown above. (8) Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. 7 -- 8 of 10 -- TOTAL PHARMACEUTICAL $9,238 $9,980 $19,218 $8,905 $8,178 $17,083 $9,714 $9,813 $36,610 22 12 United States 4,294 4,647 8,941 4,308 3,958 8,266 4,842 4,903 18,010 17 8 % Pharmaceutical Sales 46.5% 46.6% 46.5% 48.4% 48.4% 48.4% 49.8% 50.0% 49.2% Europe (1) 2,276 2,404 4,680 2,116 1,855 3,971 2,171 2,314 8,455 30 18 % Pharmaceutical Sales 24.6% 24.1% 24.4% 23.8% 22.7% 23.2% 22.3% 23.6% 23.1% China 688 944 1,632 628 600 1,228 764 670 2,661 57 33 % Pharmaceutical Sales 7.4% 9.5% 8.5% 7.1% 7.3% 7.2% 7.9% 6.8% 7.3% Japan 607 637 1,244 561 601 1,162 648 704 2,514 6 7 % Pharmaceutical Sales 6.6% 6.4% 6.5% 6.3% 7.3% 6.8% 6.7% 7.2% 6.9% Asia Pacific (other than China and Japan) 437 442 879 411 377 789 411 414 1,614 17 11 % Pharmaceutical Sales 4.7% 4.4% 4.6% 4.6% 4.6% 4.6% 4.2% 4.2% 4.4% Latin America 353 379 732 314 312 626 372 371 1,369 21 17 % Pharmaceutical Sales 3.8% 3.8% 3.8% 3.5% 3.8% 3.7% 3.8% 3.8% 3.7% Eastern Europe/Middle East/Africa 357 318 675 353 309 659 289 251 1,199 3 2 % Pharmaceutical Sales 3.9% 3.2% 3.5% 4.0% 3.8% 3.9% 3.0% 2.6% 3.3% Canada 160 157 318 159 121 280 169 149 599 31 14 % Pharmaceutical Sales 1.7% 1.6% 1.7% 1.8% 1.5% 1.6% 1.7% 1.5% 1.6% Other 66 52 117 55 45 102 48 37 189 16 15 % Pharmaceutical Sales 0.8% 0.4% 0.5% 0.5% 0.6% 0.6% 0.6% 0.3% 0.5% 2021 2020 % Change MERCK & CO., INC. PHARMACEUTICAL GEOGRAPHIC SALES - CONTINUING OPERATIONS (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3c June YTD Sum of quarterly amounts may not equal year-to-date amounts due to rounding. 1Q 2Q June YTD 1Q 2Q June YTD (1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom. 3Q 4Q Full Year 2Q 8 -- 9 of 10 -- OTHER (INCOME) EXPENSE, NET 2Q21 2Q20 June YTD 2021 June YTD 2020 Interest income (9) $ (14) $ (20) $ (39) $ Interest expense 202 209 401 421 Exchange losses 114 24 155 78 Income from investments in equity securities, net (1) (280) (551) (854) (603) Net periodic defined benefit plan (credit) cost other than service cost (110) (80) (199) (170) Other, net (20) 25 (41) (12) Total (103) $ (387) $ (558) $ (325) $ (1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while ownership interests in investment funds are accounted for on a one quarter lag. MERCK & CO., INC. OTHER (INCOME) EXPENSE, NET - GAAP (AMOUNTS IN MILLIONS) (UNAUDITED) Table 4 9 -- 10 of 10 --